BPOM Highlights Biosimilar Development for National Manufacturing

Indonesian Food and Drug Authority (BPOM) emphasized the importance of biosimilar development in enhancing the country's manufacturing capabilities for biological products. The agency stated that investment, regulatory support, and improved scientific capacity are essential for this endeavor.

BPOM Head Taruna Ikrar defined biosimilar products as biological products that are highly similar to, but not identical to, their reference biological products. He highlighted the role of these products in strengthening Indonesia's national manufacturing sector.

Currently, Indonesia's biosimilar development ecosystem includes seven biosimilar manufacturers and 159 clinical trial sites. This infrastructure is seen as a critical component in advancing the country's capacity to produce biological products.